Oncosec Medical (ONCS) KEYNOTE-695 Phase 2b Data Shows Partial Response in Two of Nine Patients, One Had Stable Disease
Tweet Send to a Friend
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS) today reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
